SRTS...The PINNACLE of the SRTS earnings cc...
RE: Intra-operative radiotherapy (IORT) for the treatment of breast and other cancers...
- "What I can tell you is that things are moving along as scheduled. So at current, we are building a system that is just about completed so that we can start its initial testing. And once we're comfortable with the product being able to pass any and all tests that are going to be required by the FDA, that's when we'll start the paperwork for the submission. So part of the reason why we've had such expense in R&D is, this was a product that was scheduled to come out maybe at the end of 2018. And if we can get it approved before the middle of next year, that just gives us significant runway to get some sales in-house because you have to keep in mind that this is a product that's going to be $800,000 to $900,000. So it's going to have significant revenue impact on the company, BUT IT'S GOING TO HAVE EVEN MORE SIGNIFICANT IMPACT IN THE TREATMENT OF PATIENTS. And that's what we're really excited about. THIS IS A GAME CHANGER AND A LIFESAVER FOR PEOPLE THAT HAVE BREAST CANCER. AND IT'S ALSO GOING TO APPLY TO CERTAIN HEAD AND NECK CANCERS, COLORECTAL, AND VAGINAL CANCERS. These things are what they call orphan cancers, and this is something that is going to be beneficial in those areas as well."
SRTS (Sensus Healthcare) is now a top holding of mine. They have a very experienced management team and the company should experience strong WORLDWIDE growth over the coming years!!!
The information posted by 2morrowsGains is opinion only and should not to be taken as investment advice.
